A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
Clinical trial NCT06188559 · COMPLETED
Trial details
- NCT number
- NCT06188559
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-10
- Primary completion
- 2026-03-18
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.